Callan JMB Announces Arrival of Rapid Dose Therapeutics’ QuickStrip™, Resulting in $15 Million in Projected Revenue Over the Next 18 months
Callan JMB says completion of the oral-film project and its recently announced IV bag facility requires no additional capital raising.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Callan JMB (NASDAQ: CJMB) has received Rapid Dose Therapeutics’ QuickStrip oral thin-film production line for installation at its Texas facility.
The equipment delivery advances the company’s planned entry into U.S. manufacturing of oral thin-film products—fast-dissolving strips carrying active ingredients. Once installed, the line is intended to support pharmaceutical, nutraceutical and government healthcare applications, combining Rapid Dose Therapeutics’ technology with Callan JMB’s logistics and distribution infrastructure.
Callan JMB projects up to $15 million in revenue during the first 18 months of operation, following successful equipment qualification. Installation and qualification remain ahead of commercial operation. The company said neither completion of this project nor its recently announced IV bag manufacturing facility requires additional capital raising.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Up to $15 million in revenue projected by Callan JMB for the first 18 months of operation after successful qualification.
- Minor pointQuickStrip production line received from Rapid Dose Therapeutics advances Callan JMB’s domestic manufacturing expansion.
- Minor point. Forward-looking: it has not happened yet and may not happen.No additional capital raising required to complete either manufacturing project, Callan JMB said.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Installation and successful equipment qualification remain prerequisites for the planned manufacturing operation and projected revenue.
Details
Market Reaction – CJMB
On Nov 2, the day this news came out, the latest delayed price for CJMB is 4.72% below the previous close. Argus tracked a peak move of +31.7% during the session. Argus tracked a trough of -24.0% from its starting point during tracking. Our momentum scanner has recorded 75 alerts for this stock so far that day. The latest delayed price is $0.40. Relative volume is exceptionally heavy at 45459.6x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Projected revenue
- Up to $15 million
- First 18 months of operation, after successful equipment qualification
Historical Context
-
Third-party non-dilutive funding covered the $16 million IV bag facility without adding debt.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Milestone advances Callan JMB’s domestic pharmaceutical manufacturing strategy and is expected to create a new high-margin healthcare manufacturing revenue stream at their Texas facility.
SPRING BRANCH, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Callan JMB, Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified healthcare logistics, preparedness, and critical infrastructure company, today announced that it has received a complete QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics Corp. (“RDT”) for installation at the Company’s facility in Texas.
The arrival of the manufacturing system completes another significant step in Callan JMB’s strategy to expand its pharmaceutical services platform through domestic manufacturing, packaging, fulfillment, distribution, and increase our healthcare preparedness capabilities. This equipment delivery launches our entry into the market for the production of innovative oral thin-film delivery products in the United States.
The collaboration comes amid growing interest in oral thin-film drug delivery technologies as demand grows for alternative pharmaceutical dosage formats. This arrangement combines RDT’s proprietary QuickStrip™ oral thin-film technology with Callan JMB’s infrastructure, regulatory expertise, healthcare logistics network, and pharmaceutical distribution capabilities. Once installed the production line will provide the foundation for U.S.-based manufacturing of fast-dissolving oral thin-film products for pharmaceutical, nutraceutical, and government healthcare applications.
Callan JMB currently believes that the oral thin-film manufacturing platform will generate up to
“This shipment is an important milestone in our vision to fast track the building of a comprehensive U.S.-based pharmaceutical manufacturing and healthcare logistics platform,” said Wayne Williams, Chief Executive Officer of Callan JMB. “We continue to implement capabilities that will help us reach our goal of strengthen healthcare supply chain resiliency, support domestic manufacturing, and create long-term value for our customers and shareholders. We believe oral thin-film delivery technology represents one of the most promising segments of pharmaceutical innovation today. Today’s positive announcement demonstrates our commitment to a rapid roll out of these advancements.”
Williams continued, “This new opportunity aligns directly with our strategy of leveraging our existing infrastructure and healthcare logistics capabilities to create scalable, recurring revenue streams while supporting domestic pharmaceutical manufacturing. Neither the completion of this project nor the recently announced IV Bag manufacturing facility require us to raise any additional capital.“
About QuickStrip™
QuickStrip™ is Rapid Dose Therapeutics’ proprietary oral thin-film drug delivery platform. The technology utilizes rapidly dissolving oral strips designed to deliver active ingredients efficiently and conveniently without the need for water or traditional dosage forms. The platform has potential applications across pharmaceuticals, nutraceuticals, wellness products, emergency preparedness programs, and other healthcare markets.
About Callan JMB
Callan JMB, Inc. (NASDAQ: CJMB) is a diversified healthcare logistics, preparedness, and manufacturing, and critical infrastructure company serving healthcare organizations, government agencies, and commercial customers. The Company provides fulfillment, warehousing, cold-chain logistics, monitoring, regulatory compliance, specialty packaging, pharmaceutical support services, and emergency preparedness solutions designed to strengthen supply chains and protect critical products.
Through strategic partnerships, acquisitions, and organic growth initiatives, Calen JMB is building a platform spanning healthcare and pharmaceutical logistics, domestic pharmaceutical manufacturing, critical electrical infrastructure, specialty industrial manufacturing, preparedness services, and energy development.
For more information, visit www.callanjmb.com.
Investor Contact
Valter Pinto
Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
(212) 896-1254
Media Contact
Arian Hopkins
ahopkins@callanjmb.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated installation, qualification, operation, commercialization, revenue generation, and future utilization of the QuickStrip™ production line; the expected benefits of the collaboration with Rapid Dose Therapeutics; projected revenues; and future business opportunities. Forward-looking statements are based on management’s current expectations and assumptions and are subject to numerous risks and uncertainties, including customer adoption, regulatory approvals, product qualification, market conditions, and execution risks. Actual results may differ materially from those described in forward-looking statements. Readers are cautioned not to place undue reliance on such statements. Callan JMB undertakes no obligation to update any forward-looking statements except as required by applicable law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue does Callan JMB expect from QuickStrip manufacturing?
Callan JMB projects up to $15 million in revenue during the first 18 months of operation, following successful qualification of the equipment. The production line has arrived for installation at the company’s Texas facility.
Does Callan JMB need to raise capital to complete its manufacturing projects?
Callan JMB said no additional capital raising is required to complete either the QuickStrip project or its recently announced IV bag manufacturing facility.